AM Finest confirms scores for Pfizer captive Blue Whale Re

AM Finest has confirmed the monetary power ranking of A (Glorious) and the long-term issuer credit standing of a+ (Glorious) for Blue Whale Re situated in Burlington, VT, the only captive for Pfizer.

The credit score company famous that these scores underscore Blue Whale’s strong stability sheet, sturdy working efficiency, impartial enterprise profile, and efficient enterprise danger administration (ERM).

Blue Whale is integral in insuring or reinsuring Pfizer’s international property exposures and performs a significant function within the firm’s overarching ERM technique to guard its belongings.

As per AM Finest, the scores mirror its capacity to cowl liabilities with vital retentions and the assist of a various and substantial reinsurance program. It notes the standard of the reinsurers concerned and the intensive monetary assets accessible to the captive as a part of the Pfizer household.

The captive’s working efficiency has been favorable, demonstrating low common loss and minimal expense ratios in comparison with its trade friends. Regardless of the potential for average volatility as a consequence of its excessive retentions for low-frequency, high-severity protection, the efficiency in 2023 was inside acceptable danger tolerance ranges.

As a completely owned subsidiary of Pfizer, Blue Whale was established to insure or reinsure particular dangers related to its mother or father group. In response to current onerous market situations, Blue Whale has strategically opted to take smaller parts of its disaster tower to maximise financial effectivity for Pfizer.

Moreover, it has supplied capability for cyber legal responsibility protection in response to difficult market pricing.

Potential adverse ranking actions may very well be prompted if AM Finest perceives any change in Pfizer’s capacity or willingness to assist Blue Whale, which might impression the captive insurer’s operational stance and monetary robustness.

What are your ideas on this story? Please be happy to share your feedback beneath.